My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 338

    1.

    The effect of pioglitazone on the liver: role of adiponectin.

    Gastaldelli A, Miyazaki Y, Mahankali A, Berria R, Pettiti M, Buzzigoli E, Ferrannini E, DeFronzo RA.

    Diabetes Care. 2006 Oct;29(10):2275-81.PMID: 17003306 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.

    Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA.

    J Clin Endocrinol Metab. 2004 Sep;89(9):4312-9.PMID: 15356026 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.

    Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA.

    J Clin Endocrinol Metab. 2004 Jan;89(1):200-6.PMID: 14715850 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.

    Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA.

    Diabetes Care. 2001 Apr;24(4):710-9.PMID: 11315836 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes.

    Gastaldelli A, Miyazaki Y, Pettiti M, Santini E, Ciociaro D, Defronzo RA, Ferrannini E.

    J Clin Endocrinol Metab. 2006 Mar;91(3):806-12. Epub 2005 Dec 13.PMID: 16352689 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

    Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA.

    Diabetologia. 2007 Aug;50(8):1723-31. Epub 2007 May 23.PMID: 17520238 [PubMed - indexed for MEDLINE]Related articles

    7.

    Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes.

    Gastaldelli A, Casolaro A, Pettiti M, Nannipieri M, Ciociaro D, Frascerra S, Buzzigoli E, Baldi S, Mari A, Ferrannini E.

    Clin Pharmacol Ther. 2007 Feb;81(2):205-12.PMID: 17259945 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.

    Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA.

    J Clin Endocrinol Metab. 2002 Jun;87(6):2784-91.PMID: 12050251 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients.

    Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA.

    Int J Obes Relat Metab Disord. 2004 Jun;28(6):783-9.PMID: 15024400 [PubMed - indexed for MEDLINE]Related articles

    10.

    Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.

    Miyazaki Y, Matsuda M, DeFronzo RA.

    Diabetes Care. 2002 Mar;25(3):517-23.PMID: 11874940 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.

    Fernandez M, Triplitt C, Wajcberg E, Sriwijilkamol AA, Musi N, Cusi K, DeFronzo R, Cersosimo E.

    Diabetes Care. 2008 Jan;31(1):121-7. Epub 2007 Oct 1.PMID: 17909084 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.

    Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E, Defronzo RA.

    Gastroenterology. 2007 Aug;133(2):496-506. Epub 2007 May 1.PMID: 17681171 [PubMed - indexed for MEDLINE]Related articles

    13.

    Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.

    Basu R, Shah P, Basu A, Norby B, Dicke B, Chandramouli V, Cohen O, Landau BR, Rizza RA.

    Diabetes. 2008 Jan;57(1):24-31. Epub 2007 Oct 3.PMID: 17914032 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.

    Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM.

    Diabetes. 2002 Oct;51(10):2968-74.PMID: 12351435 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.

    Triplitt C, Glass L, Miyazaki Y, Wajcberg E, Gastaldelli A, De Filippis E, Cersosimo E, DeFronzo RA.

    Diabetes Care. 2006 Nov;29(11):2371-7.PMID: 17065670 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Thiazolidinediones improve beta-cell function in type 2 diabetic patients.

    Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA.

    Am J Physiol Endocrinol Metab. 2007 Mar;292(3):E871-83. Epub 2006 Nov 14.PMID: 17106061 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes.

    Boden G, Chen X, Capulong E, Mozzoli M.

    Diabetes. 2001 Apr;50(4):810-6.PMID: 11289046 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 diabetes treated with pioglitazone.

    Wajcberg E, Sriwijitkamol A, Musi N, DeFronzo RA, Cersosimo E.

    J Clin Endocrinol Metab. 2007 Apr;92(4):1256-62. Epub 2007 Jan 23.PMID: 17244785 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.

    Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA.

    Diabetes. 2003 Jun;52(6):1364-70.PMID: 12765945 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients.

    Gastaldelli A, Toschi E, Pettiti M, Frascerra S, Quiñones-Galvan A, Sironi AM, Natali A, Ferrannini E.

    Diabetes. 2001 Aug;50(8):1807-12.PMID: 11473042 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is temporarily unavailable.

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    » See more...